Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01887717 · ClinicalTrials.gov registry record · Phase 3
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Phase 3 study, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 36
- Enrollment target
NCT01887717 is a Phase 3 study that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 36 participants.
The verdict
NCT01887717, a Phase 3 study, was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a two-arm, open-label, prospective, multi-center, randomized, active-controlled clinical trial to assess efficacy and safety of TheraSphere in comparison to standard of care therapy (sorafenib) in the treatment of participants with inoperable liver cancer and blockage of the portal vein.
Interventions
- DRUG Sorafenib
- DEVICE TheraSphere®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-02-27 |
| Est. Completion | 2017-05-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01887717
The ClinicalTrials.gov registry entry for NCT01887717 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT01887717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01887717 about?
NCT01887717 is a clinical study titled "Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein". This is a two-arm, open-label, prospective, multi-center, randomized, active-controlled clinical trial to assess efficacy and safety of TheraSphere in comparison to standard of care therapy (sorafenib) in the treatment of participants with inoperable liver cancer and blockage of the portal vein.
What is the current status of trial NCT01887717?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 36 participants. The study started on 2014-02-27. Estimated completion is 2017-05-23.
What interventions are being tested in trial NCT01887717?
The interventions under investigation include: Sorafenib (DRUG), TheraSphere® (DEVICE).
Who is sponsoring clinical trial NCT01887717?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.